Cocrystal Pharma’s First Oral Norovirus Protease Inhibitor CDI-988 to be Featured at the International Society for Antiviral Research Conference (ICAR) 2026
Cocrystal Pharma, Inc. (COCP)
NASDAQ:AMEX Investor Relations:
cocrystalpharma.com
Company Research
Source: GlobeNewswire
CDI-988 is the first oral antiviral drug candidate being developed for prevention and treatment of norovirus infectionsCompany to present Phase 1 data and updates from ongoing Phase 1b study conducted at Emory University School of MedicineNo approved antiviral therapies or vaccines for norovirus infections demonstrate an immediate market need BOTHELL, Wash., Feb. 19, 2026 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”) announces that initial progress of a norovirus challenge study with its direct-acting, oral protease inhibitor CDI-988 will be presented at the 39th International Conference on Antiviral Research (ICAR2026), being held April?27–May?1?in Prague, Czech Republic. CDI-988 is the first oral antiviral drug candidate under development for the prevention and treatment of acute norovirus gastroenteritis. Sam?Lee,?Ph.D., Cocrystal President and co-CEO, will discuss the ongoing Phase 1b challenge study evaluating CDI-988 as both a poten
Show less
Read more
Impact Snapshot
Event Time:
COCP
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
COCP alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
COCP alerts
High impacting Cocrystal Pharma, Inc. news events
Weekly update
A roundup of the hottest topics
COCP
News
- Cocrystal Pharma's First Oral Norovirus Protease Inhibitor CDI-988 to be Featured at the International Society for Antiviral Research Conference (ICAR) 2026 [Yahoo! Finance]Yahoo! Finance
- Cocrystal Pharma Receives IRB Approval from Emory University School of Medicine for Phase 1b Human Challenge Study with CDI-988 for Prevention and Treatment of Norovirus [Yahoo! Finance]Yahoo! Finance
- Cocrystal Pharma Receives IRB Approval from Emory University School of Medicine for Phase 1b Human Challenge Study with CDI-988 for Prevention and Treatment of NorovirusGlobeNewswire
COCP
Earnings
- 5/15/25 - Beat
COCP
Sec Filings
- 2/25/26 - Form 4
- 2/19/26 - Form 8-K
- 2/9/26 - Form 4
- COCP's page on the SEC website